Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

Abstract Background Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidias...

Full description

Bibliographic Details
Published in:	BMC Oral Health
Main Authors:	Bruna Lavinas Sayed Picciani, Arkadiusz Dziedzic, Juliana Tristão Werneck, Marcello Alves Marinho, Thaylla Núñez Amin Dick, Nara Regina Quintanilha, Eliane Pedra Dias
Format:	Article
Language:	English
Published:	BMC 2021-06-01
Subjects:	Oral candidiasis Secukinumab Psoriasis Interleukin 17 inhibitor (anti IL-17)
Online Access:	https://doi.org/10.1186/s12903-021-01653-6

Similar Items

Nonscrapable yeast: A case of chronic hyperplastic candidiasis following secukinumab therapy
by: Gabriela A. Duchesne, BS, et al.
Published: (2025-09-01)

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
by: Hazrat Bilal, et al.
Published: (2024-01-01)

Secukinumab
by: Nilgün Atakan
Published: (2022-04-01)

Oral <i>Candida</i> Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature
by: Efstathios Pettas, et al.
Published: (2021-12-01)

Chronic Hyperplastic Candidiasis—An Adverse Event of Secukinumab in the Oral Cavity: A Case Report and Literature Review
by: Ana Glavina, et al.
Published: (2025-08-01)

Secukinumab‐induced lichen planus
by: Jihane Belcadi, et al.
Published: (2024-06-01)

Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
by: T. V. Korotaeva, et al.
Published: (2017-04-01)

Asymptomatic microscopic colitis induced by secukinumab
by: Matteo Megna, MD, et al.
Published: (2024-06-01)

Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study
by: Shuangmei Zhang, et al.
Published: (2025-10-01)

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching
by: Giovanni Damiani, et al.
Published: (2022-01-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Secukinumab-induced Oral Lichen Planus: A Report of Case and Review of Literature
by: Munise Daye, et al.
Published: (2021-08-01)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)

Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis
by: Zhang C, et al.
Published: (2023-10-01)

Awareness of the Risk of Paradoxical Psoriasis in Patients with SAPHO Syndrome Undergoing Treatment with Secukinumab: A Case Series
by: Xu C, et al.
Published: (2025-03-01)

Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis
by: Kiran Godse
Published: (2017-01-01)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
by: Talamonti M, et al.
Published: (2023-04-01)

Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
by: Bucur S, et al.
Published: (2024-06-01)

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
by: Karel Pavelka, et al.
Published: (2017-12-01)

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
by: Vishnu Eshwar, et al.
Published: (2022-11-01)

Herpetiform aphthous ulcerations induced by secukinumab: Report of 2 cases
by: Michael Benzaquen, MD, et al.
Published: (2020-10-01)

Secukinumab treatment in a pediatric patient with corticosteroid-intolerant pyoderma gangrenosum: a case report
by: Wang Liwei, et al.
Published: (2025-10-01)

IL-17 in Protective Immunity to Vaginal Candidiasis
by: Baghdad Science Journal
Published: (2016-03-01)

Comparative Immunomodulatory Efficacy of Secukinumab and Honokiol in Experimental Asthma and Acute Lung Injury
by: Andrei Gheorghe Vicovan, et al.
Published: (2025-07-01)

Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis
by: Yingzhe Yu, et al.
Published: (2025-08-01)

Case report: Successful treatment of acute generalized pustular psoriasis of puerperium with secukinumab
by: Gao Xue, et al.
Published: (2022-12-01)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
by: Alexis Ogdie, et al.
Published: (2023-05-01)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: L. C. Coates, et al.
Published: (2018-12-01)

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
by: Tommaso Lupia, et al.
Published: (2022-10-01)

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
by: Lu Xing, et al.
Published: (2025-12-01)

The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study
by: İncilay Kalay Yıldızhan, et al.
Published: (2021-09-01)

Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
by: Jui-Cheng Tseng, et al.
Published: (2020-11-01)

Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
by: Arfenya E. Karamova, et al.
Published: (2025-06-01)

INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Protective effect of Secukinumab on severe sepsis model rats by neutralizing IL-17A to inhibit IKBα/NFκB inflammatory signal pathway
by: Xingsheng Wang, et al.
Published: (2022-10-01)

Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study
by: Tong Wu, et al.
Published: (2024-12-01)

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)
by: Francisco Javier Melgosa Ramos, et al.
Published: (2023-09-01)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
by: N. A. Shostak, et al.
Published: (2022-10-01)

Response to Secukinumab Treatment in Active Psoriatic Arthritis Patients- Single Center Experience
by: Ayşe Bahar Keleşoğlu Dinçer, et al.
Published: (2021-08-01)